• Simone Lanini, Alimuddin Zumla, John P A Ioannidis, Antonino Di Caro, Sanjeev Krishna, Lawrence Gostin, Enrico Girardi, Michel Pletschette, Gino Strada, Aldo Baritussio, Gina Portella, Giovanni Apolone, Silvio Cavuto, Roberto Satolli, Peter Kremsner, Francesco Vairo, and Giuseppe Ippolito.
• National institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy. Electronic address: simone.lanini@inmi.it.
• Lancet Infect Dis. 2015 Jun 1;15(6):738-45.

AbstractThe Ebola outbreak that has devastated parts of west Africa represents an unprecedented challenge for research and ethics. Estimates from the past three decades emphasise that the present effort to contain the epidemic in the three most affected countries (Guinea, Liberia, and Sierra Leone) has been insufficient, with more than 24,900 cases and about 10,300 deaths, as of March 25, 2015. Faced with such an exceptional event and the urgent response it demands, the use of randomised controlled trials (RCT) for Ebola-related research might be both unethical and infeasible and that potential interventions should be assessed in non-randomised studies on the basis of compassionate use. However, non-randomised studies might not yield valid conclusions, leading to large residual uncertainty about how to interpret the results, and can also waste scarce intervention-related resources, making them profoundly unethical. Scientifically sound and rigorous study designs, such as adaptive RCTs, could provide the best way to reduce the time needed to develop new interventions and to obtain valid results on their efficacy and safety while preserving the application of ethical precepts. We present an overview of clinical studies registered at present at the four main international trial registries and provide a simulation on how adaptive RCTs can behave in this context, when mortality varies simultaneously in either the control or the experimental group.Copyright © 2015 Elsevier Ltd. All rights reserved.

12 keywords...

hide…